Ashton Thomas Private Wealth LLC Acquires 2,101 Shares of Gilead Sciences, Inc. $GILD

Ashton Thomas Private Wealth LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% in the second quarter, HoldingsChannel.com reports. The fund owned 47,869 shares of the biopharmaceutical company’s stock after purchasing an additional 2,101 shares during the period. Ashton Thomas Private Wealth LLC’s holdings in Gilead Sciences were worth $5,307,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of GILD. Price T Rowe Associates Inc. MD boosted its position in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. Nuveen LLC bought a new stake in shares of Gilead Sciences during the 1st quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $238,083,000. Los Angeles Capital Management LLC boosted its position in shares of Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after acquiring an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after acquiring an additional 1,942,433 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $120.47 on Tuesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The business’s 50 day simple moving average is $115.52 and its two-hundred day simple moving average is $111.21. The stock has a market capitalization of $149.48 billion, a P/E ratio of 24.00, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a one year low of $86.08 and a one year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same period in the previous year, the firm earned $2.01 earnings per share. The business’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the transaction, the chief executive officer directly owned 591,203 shares in the company, valued at $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,500 shares of company stock valued at $7,142,140. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research reports. TD Cowen raised their price objective on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. BMO Capital Markets raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a report on Monday, October 20th. Citigroup raised their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $122.61.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.